Lowest-Rated StocksLowest-RatedNASDAQ:ELEV Elevation Oncology (ELEV) Stock Price, News & Analysis $0.36 0.00 (0.00%) As of 07/23/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Elevation Oncology Stock (NASDAQ:ELEV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Elevation Oncology alerts:Sign Up Key Stats Today's Range$0.37▼$0.3750-Day Range$0.30▼$0.3952-Week Range$0.22▼$3.09VolumeN/AAverage Volume1.18 million shsMarket Capitalization$21.62 millionP/E RatioN/ADividend YieldN/APrice Target$3.39Consensus RatingHold Company Overview Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts. Read More Elevation Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreELEV MarketRank™: Elevation Oncology scored higher than 57% of companies evaluated by MarketBeat, and ranked 469th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingElevation Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageElevation Oncology has only been the subject of 4 research reports in the past 90 days.Read more about Elevation Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Elevation Oncology are expected to decrease in the coming year, from ($0.84) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elevation Oncology is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elevation Oncology is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElevation Oncology has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Elevation Oncology's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.92% of the float of Elevation Oncology has been sold short.Short Interest Ratio / Days to CoverElevation Oncology has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elevation Oncology has recently decreased by 31.58%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElevation Oncology does not currently pay a dividend.Dividend GrowthElevation Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.92% of the float of Elevation Oncology has been sold short.Short Interest Ratio / Days to CoverElevation Oncology has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elevation Oncology has recently decreased by 31.58%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.37 News SentimentElevation Oncology has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Elevation Oncology this week, compared to 1 article on an average week.Search Interest1 people have searched for ELEV on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Elevation Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elevation Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Elevation Oncology is held by insiders.Percentage Held by Institutions83.70% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Elevation Oncology's insider trading history. Receive ELEV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address ELEV Stock News HeadlinesElevation Oncology Terminates License Agreement with CSPCJuly 25 at 5:05 PM | theglobeandmail.comElevation Oncology Completes Merger with Concentra BiosciencesJuly 23 at 10:22 AM | tipranks.comThis tiny loophole could hand you massive winners…Top institutions are raising their year-end targets for one of the biggest assets out there… Several weeks ago, Standard Chartered’s Head of Digital Assets revised his target for Q2 2025 from $120k… openly acknowledging $200K is in play. And with the kind of momentum we’ve seen from this top asset - Bitcoin - in recent weeks, I wouldn’t be surprised if it hits that target in the coming months. In fact, from what I’m seeing, the stars are aligned for a bull run… and its next leg up could be just around the corner.July 25 at 2:00 AM | ProsperityPub (Ad)Elevation Oncology, Inc. (NASDAQ:ELEV) Given Consensus Rating of "Hold" by BrokeragesJuly 22 at 6:15 AM | americanbankingnews.comElevation Oncology (NASDAQ:ELEV) Stock Price Down 0.1% - Should You Sell?July 19, 2025 | americanbankingnews.comELEV - Elevation Oncology Inc Sustainability | MorningstarJuly 11, 2025 | morningstar.comMHAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)June 15, 2025 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of ShareholdersJune 12, 2025 | prnewswire.comSee More Headlines ELEV Stock Analysis - Frequently Asked Questions How have ELEV shares performed this year? Elevation Oncology's stock was trading at $0.5626 at the start of the year. Since then, ELEV shares have decreased by 35.1% and is now trading at $0.3650. How were Elevation Oncology's earnings last quarter? Elevation Oncology, Inc. (NASDAQ:ELEV) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.04. When did Elevation Oncology IPO? Elevation Oncology (ELEV) raised $1 billion in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 63,000,000 shares at a price of $15.00-$17.00 per share. Who are Elevation Oncology's major shareholders? Elevation Oncology's top institutional shareholders include Deltec Asset Management LLC (2.43%). View institutional ownership trends. How do I buy shares of Elevation Oncology? Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Elevation Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elevation Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/15/2025Today7/25/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELEV CIK1783032 Webwww.elevationoncology.com Phone716-371-1125FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Elevation Oncology$3.39 High Price Target$8.00 Low Price Target$0.70 Potential Upside/Downside+827.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.68% Return on Assets-48.14% Debt Debt-to-Equity Ratio0.67 Current Ratio19.40 Quick Ratio19.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.02 per share Price / Book0.36Miscellaneous Outstanding Shares59,220,000Free Float54,427,000Market Cap$21.62 million OptionableOptionable Beta1.48 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ELEV) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.